

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

COSMO TECHNOLOGIES LIMITED,
Patent Owner.

U.S. Patent No. 9,320,716 to Villa *et al.*
Issue Date: April 26, 2016

Title: Controlled Release and Taste Masking Oral Pharmaceutical Compositions

Inter Partes Review No.: IPR2017-01035

**Petition for *Inter Partes* Review of U.S. Patent No. 9,320,716 Under
35 U.S.C. §§ 311-319 and 37 C.F.R. §§ 42.1-.80, 42.100-.123**

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION	1
II. OVERVIEW	1
III. STANDING (37 C.F.R. § 42.104(a); PROCEDURAL STATEMENTS).....	1
IV. MANDATORY NOTICES (37 C.F.R. § 42.8(a)(1)).....	2
A. Each Real Party-In-Interest (37 C.F.R. § 42.8(b)(1))	2
B. Notice of Related Matters (37 C.F.R. § 42.8(b)(2)).....	2
1. Judicial Matters	2
2. Administrative Matters	2
C. Designation of Lead and Back-Up Counsel and Service (37 C.F.R. §§ 42.8(b)(3), 42.8(b)(4), 42.10(a), and 42.10(b)):	3
V. STATEMENT OF THE PRECISE RELIEF REQUESTED AND THE REASONS THEREFORE (37 C.F.R. § 42.22(a))	3
VI. THE '716 PATENT	4
A. Claim Construction.....	5
VII. A PERSON OF ORDINARY SKILL IN THE ART	6
VIII. IDENTIFICATION OF CHALLENGE (37 C.F.R. § 42.104(b)).....	7
IX. INVALIDITY ANALYSIS	9
A. Ground 1: U.S. Patent No. 5,681,584 Anticipates Claims 1-29	9
1. Disclosure of the '584 Patent.....	10
2. Analysis of Independent Claims 1, 12 and 22	10
3. Analysis of Dependent Claims	19

B.	Ground 2: Claims 1-29 are Rendered Obvious by U.S. Patent No. 5,681,584	23
1.	The Level of Ordinary Skill in the Pertinent Art and the Scope and Content of the Prior Art.....	23
2.	Differences Between the Claims and the Prior Art	24
a.	Claim 1.....	24
b.	Claims 6, 12, and 22: “at least one amphiphilic compound”.....	30
c.	Claims 2 and 13: “wherein the gastro-resistant coating is . . . methacrylic acid polymers and cellulose derivatives”.....	31
d.	Claims 3-5 and 14-16: “wherein the at least one hydrophilic compound is . . . a hydroxyalkyl cellulose”	32
e.	Claims 7, 8, 17 and 18: “wherein the at least one amphiphilic compound . . . lecithin”	32
a.	Claims 9, 10, 19 and 20: “wherein the at least one lipophilic compound is . . . an unsaturated or hydrogenated alcohol or fatty acid, salt, ester, or amide thereof . . .”/“lipophilic compound is stearic acid”	33
b.	Claims 11, 21 and 23: “The controlled release oral pharmaceutical composition . . . further comprising . . . an acrylic acid polymer”.....	34
c.	Claims 24, 25 and 26: “wherein the macroscopically homogenous structure comprises microcrystalline cellulose”	35
d.	Claims 27, 28 and 29: “A method for treating intestinal inflammatory disease comprising administering to a patient the controlled release oral pharmaceutical composition according to claim [1/12/22]”.....	36
e.	Reasonable Expectation of Success.....	37
C.	Ground 3: U.S. Patent No. 5,811,388 Anticipates Claims 1-7, 9, 11-17, 19 and 21-29.....	38
1.	Disclosure of the ’388 Patent.....	39

2.	Analysis of Independent Claims 1, 12 and 22	39
3.	Analysis of Dependent Claims 2-7, 9, 11, 13-17, 19, 21, and 23-29.....	47
D.	Ground 4: U.S. Patent No. 5,811,388 Renders Obvious Claims 1-29.....	50
1.	Differences Between the Claims and the Prior Art	51
a.	Claim 1.....	51
b.	Claims 6, 12, and 22: “at least one amphiphilic compound”	53
c.	Claims 2 and 13: “wherein the gastro-resistant coating is . . . methacrylic acid polymers and cellulose derivatives”	54
d.	Claims 3-5 and 14-16: “wherein the at least one hydrophilic compound is . . . a hydroxyalkyl cellulose”	55
e.	Claims 7, 8, 17 and 18: “wherein the at least one amphiphilic compound is . [phosphatidylcholines/lecithin]”	55
f.	Claims 9, 10, 19 and 20: “wherein the at least one lipophilic compound is . . . an unsaturated or hydrogenated alcohol or fatty acid, salt, ester, or amide thereof”/“lipophilic compound is stearic acid”	57
g.	Claims 11, 21 and 23: “The controlled release oral pharmaceutical composition . . . further comprising an acrylic acid polymer”	57
h.	Claims 24, 25 and 26: “wherein the macroscopically homogenous structure comprises microcrystalline cellulose”	58
i.	Claims 27, 28 and 29: “A method for treating intestinal inflammatory disease comprising administering to a patient the controlled release oral pharmaceutical composition according to claim [1/12/22]”	59
a.	Reasonable Expectation of Success.....	60

E.	Ground 5: U.S. Patent No. 5,811,388 in View of U.S. Patent No. 5,681,584 Renders Obvious Claims 8, 10, 18, and 20.....	60
1.	Differences Between the Claims and the Prior Art	61
a.	Claims 8 and 18: “wherein the at least one amphiphilic compound is . . . lecithin.”.....	61
b.	Claims 10 and 20: “wherein the at least one lipophilic compound is stearic acid”	62
F.	Objective Indicia of Non-Obviousness	63
1.	No Long-Felt Unmet Need	64
2.	No Failure of Others	64
3.	No Unexpected Results Over the Closest Prior Art.....	65
4.	No Commercial Success	66
X.	CONCLUSION.....	66

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.